Literature DB >> 20567626

Consensus recommendations for the diagnosis and management of well-differentiated gastroenterohepatic neuroendocrine tumours: a revised statement from a Canadian National Expert Group.

W Kocha1, J Maroun, H Kennecke, C Law, P Metrakos, J F Ouellet, R Reid, C Rowsell, A Shah, S Singh, S Van Uum, R Wong.   

Abstract

Well-differentiated neuroendocrine tumours (nets-previously called "carcinoid tumours") are relatively rare tumours originating from the diffuse neuroendocrine system; they are found most often in the bronchial or gastrointestinal systems. In Canada, gastroenterohepatic NETS represent less than 0.25% of oncology cases. Because of the relative rarity of these tumours, diagnostic and therapeutic approaches vary and are often based on individual physician experience. A number of European and North American groups have developed consensus guidelines for the diagnosis and management of well-differentiated gastroenterohepatic NETS, and in 2006, Canadian consensus guidelines were published by a Canadian expert group. The updated and expanded current Canadian guidelines are based on a consensus meeting held in Paris, France, in 2008 and are based on the most current literature.

Entities:  

Keywords:  Carcinoid tumour; carcinoid heart disease; carcinoid syndrome; clinical management; diagnosis; guidelines; neuroendocrine tumours; surgery

Year:  2010        PMID: 20567626      PMCID: PMC2880904          DOI: 10.3747/co.v17i3.484

Source DB:  PubMed          Journal:  Curr Oncol        ISSN: 1198-0052            Impact factor:   3.677


  85 in total

Review 1.  [Imaging of neuroendocrine tumors of the pancreas].

Authors:  C Vick; C J Zech; S Höpfner; T Waggershauser; M Reiser
Journal:  Radiologe       Date:  2003-04       Impact factor: 0.635

Review 2.  Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS).

Authors:  U Plöckinger; G Rindi; R Arnold; B Eriksson; E P Krenning; W W de Herder; A Goede; M Caplin; K Oberg; J C Reubi; O Nilsson; G Delle Fave; P Ruszniewski; H Ahlman; B Wiedenmann
Journal:  Neuroendocrinology       Date:  2005-04-18       Impact factor: 4.914

Review 3.  Carcinoid heart disease.

Authors:  Sanjeev Bhattacharyya; Joseph Davar; Gilles Dreyfus; Martyn E Caplin
Journal:  Circulation       Date:  2007-12-11       Impact factor: 29.690

4.  An analysis of 8305 cases of carcinoid tumors.

Authors:  I M Modlin; A Sandor
Journal:  Cancer       Date:  1997-02-15       Impact factor: 6.860

Review 5.  Metastatic carcinoid tumors: a clinical review.

Authors:  Johanna M Zuetenhorst; Babs G Taal
Journal:  Oncologist       Date:  2005-02

6.  Somatostatin receptor scintigraphy in patients with carcinoid tumors.

Authors:  D J Kwekkeboom; E P Krenning
Journal:  World J Surg       Date:  1996-02       Impact factor: 3.352

Review 7.  The diagnosis and medical management of advanced neuroendocrine tumors.

Authors:  Gregory A Kaltsas; G Michael Besser; Ashley B Grossman
Journal:  Endocr Rev       Date:  2004-06       Impact factor: 19.871

8.  Echocardiographic and biochemical evaluation of the development and progression of carcinoid heart disease.

Authors:  W D Denney; W E Kemp; L B Anthony; J A Oates; B F Byrd
Journal:  J Am Coll Cardiol       Date:  1998-10       Impact factor: 24.094

9.  TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system.

Authors:  G Rindi; G Klöppel; H Alhman; M Caplin; A Couvelard; W W de Herder; B Erikssson; A Falchetti; M Falconi; P Komminoth; M Körner; J M Lopes; A-M McNicol; O Nilsson; A Perren; A Scarpa; J-Y Scoazec; B Wiedenmann
Journal:  Virchows Arch       Date:  2006-09-12       Impact factor: 4.064

10.  Guidelines for the diagnosis and management of carcinoid tumours. Part 1: the gastrointestinal tract. A statement from a Canadian National Carcinoid Expert Group.

Authors:  J Maroun; W Kocha; L Kvols; G Bjarnason; E Chen; C Germond; S Hanna; P Poitras; D Rayson; R Reid; J Rivera; A Roy; A Shah; L Sideris; L Siu; R Wong
Journal:  Curr Oncol       Date:  2006-04       Impact factor: 3.677

View more
  17 in total

1.  CT evaluation of response in advanced gastroenteropancreatic neuroendocrine tumors treated with long-acting-repeatable octreotide: what is the optimal size variation threshold?

Authors:  Yanji Luo; Jie Chen; Bingqi Shen; Meng Wang; Huasong Cai; Ling Xu; Luohai Chen; Minhu Chen; Zi-Ping Li; Shi-Ting Feng
Journal:  Eur Radiol       Date:  2018-06-06       Impact factor: 5.315

2.  Cost comparison of 111In-DTPA-octreotide scintigraphy and 68Ga-DOTATOC PET/CT for staging enteropancreatic neuroendocrine tumours.

Authors:  Nils F Schreiter; Winfried Brenner; Munenobu Nogami; Ralph Buchert; Alexander Huppertz; Ulrich-Frank Pape; Vikas Prasad; Bernd Hamm; Martin H Maurer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-09-17       Impact factor: 9.236

3.  Distribution, incidence, and prognosis in neuroendocrine tumors: a population based study from a cancer registry.

Authors:  Adele Caldarella; Emanuele Crocetti; Eugenio Paci
Journal:  Pathol Oncol Res       Date:  2011-04-09       Impact factor: 3.201

4.  Ki-67 is a reliable pathological grading marker for neuroendocrine tumors.

Authors:  Ashlie Nadler; Moises Cukier; Corwyn Rowsell; Sepideh Kamali; Yael Feinberg; Simron Singh; Calvin H L Law
Journal:  Virchows Arch       Date:  2013-04-16       Impact factor: 4.064

5.  Serum chromogranin A levels for the diagnosis and follow-up of well-differentiated non-functioning neuroendocrine tumors.

Authors:  Yuejuan Cheng; Zhao Sun; Chunmei Bai; Xiaoyan Yan; Ran Qin; Changting Meng; Hongyan Ying
Journal:  Tumour Biol       Date:  2015-09-26

6.  Eastern Canadian Gastrointestinal Cancer Consensus Conference 2014.

Authors:  E Tsvetkova; S Sud; N Aucoin; J Biagi; R Burkes; B Samson; S Brule; C Cripps; B Colwell; C Falkson; M Dorreen; R Goel; F Halwani; J Maroun; N Michaud; M Tehfe; M Thirlwell; M Vickers; T Asmis
Journal:  Curr Oncol       Date:  2015-08       Impact factor: 3.677

7.  Cost-effectiveness of everolimus for the treatment of advanced neuroendocrine tumours of gastrointestinal or lung origin in Canada.

Authors:  A Chua; A Perrin; J F Ricci; M P Neary; M Thabane
Journal:  Curr Oncol       Date:  2018-02-28       Impact factor: 3.677

Review 8.  A rare combination of an endocrine tumour of the common bile duct and a follicular lymphoma of the ampulla of Vater: a case report and review of the literature.

Authors:  Panagiotis G Athanasopoulos; Nikolaos Arkadopoulos; Vania Stafyla; Aliki Tympa; Evi Kairi; Charlotte Ryzman-Louloudis; Vassilios Smyrniotis
Journal:  World J Surg Oncol       Date:  2011-01-14       Impact factor: 2.754

9.  Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis.

Authors:  Jaume Capdevila; Isabel Sevilla; Vicente Alonso; Luís Antón Aparicio; Paula Jiménez Fonseca; Enrique Grande; Juan José Reina; José Luís Manzano; Juan Domingo Alonso Lájara; Jorge Barriuso; Daniel Castellano; Javier Medina; Carlos López; Ángel Segura; Sergio Carrera; Guillermo Crespo; José Fuster; Javier Munarriz; Pilar García Alfonso
Journal:  BMC Cancer       Date:  2015-07-04       Impact factor: 4.430

Review 10.  Nuclear medicine imaging of gastro-entero-pancreatic neuroendocrine tumors. The key role of cellular differentiation and tumor grade: from theory to clinical practice.

Authors:  Edmond Rust; Fabrice Hubele; Ettore Marzano; Bernard Goichot; Patrick Pessaux; Jean-Emmanuel Kurtz; Alessio Imperiale
Journal:  Cancer Imaging       Date:  2012-05-21       Impact factor: 3.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.